MAPT and early-onset autosomal dominant Alzheimer disease: (2) Trofinetide lacks any published preclinical data in transgenic Alzheimer’s disease mouse models (APP/PS1, 3xTg-AD, 5xFAD), tau transgenic models, or human AD-derived cellular systems (iPSC neurons, brain organoids).